Microbiome Based Therapeutics Articles & Analysis
2 articles found
Background: Disruption of the microbiome is key to the pathogenesis of recurrent Clostridioides difficile infection (CDI). Place bo-control led trials assessing microbiome therapeutics have demonstrated efficacy in recurrent CDI; hov/ever, long-term safety and efficacy data from rigorously conducted studies of microbiome therapies, including cumulative efficacy in those who received a second dose ...
Biosortia is building the world’s largest library of microbiome-derived compounds for therapeutic and other applications, by leveraging the company’s microbial harvesting platform to sample and mine aquatic microbiomes at unprecedented scales with sustainable and environmentally friendly approaches. Biosortia is seeking partners interested in accessing compounds and chemistries to ...